Structure Therapeutics (GPCR) EBIT (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly EBIT of -$89.4 million for Q1 2026, down 58.72% year-over-year from -$216.5 million in Q1 2025, and down 472.58% quarter-over-quarter from $24.0 million in Q4 2025.
Structure Therapeutics (GPCR) EBIT (2022 - 2026) Analysis & Trends
Structure Therapeutics' EBIT history runs 5 years deep, the most recent figure standing at -$89.4 million for Q1 2026.
- In Q1 2026, EBIT fell 58.72% year-over-year to -$89.4 million; the TTM figure through Mar 2026 stood at -$209.6 million (down 14.85% YoY), while the FY2025 annual figure was -$176.6 million, down 11.59% from the prior year.
- EBIT for Q1 2026 stood at -$89.4 million, down from $24.0 million in the prior quarter.
- The five-year high for EBIT was $24.0 million in Q4 2025, with the low at -$89.4 million in Q1 2026.
- The 5-year median for EBIT is -$31.0 million (2023), against an average of -$34.1 million.
- The sharpest annual moves came in 2023 and 2025: EBIT slumped 139.23% in 2023, then soared 150.97% in 2025.
- Structure Therapeutics' EBIT stood at -$13.0 million in 2022, then plunged by 139.23% to -$31.0 million in 2023, then tumbled by 51.84% to -$47.1 million in 2024, then jumped by 150.97% to $24.0 million in 2025, then slumped by 472.58% to -$89.4 million in 2026.
- Business Quant data shows GPCR's EBIT at -$89.4 million in Q1 2026, $24.0 million in Q4 2025, and -$73.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -118.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -118.63 Mn |
| Mar 31, 2026 | -89.38 Mn |
| Dec 31, 2025 | 23.99 Mn |
| Sep 30, 2025 | -73.79 Mn |
| Jun 30, 2025 | -70.45 Mn |
| Mar 31, 2025 | -56.31 Mn |
| Dec 31, 2024 | -47.06 Mn |
| Sep 30, 2024 | -45.84 Mn |
| Jun 30, 2024 | -33.32 Mn |
| Mar 31, 2024 | -32.02 Mn |
| Dec 31, 2023 | -30.99 Mn |
| Sep 30, 2023 | -26.15 Mn |
| Jun 30, 2023 | -25.99 Mn |
| Mar 31, 2023 | -19.65 Mn |
| Dec 31, 2022 | -12.96 Mn |
| Sep 30, 2022 | -12.69 Mn |
| Jun 30, 2022 | -13.96 Mn |
| Mar 31, 2022 | -12.95 Mn |